ClinicalTrials.gg
Active, not recruitingNCT05457257Updated Apr 21, 2026Results posted

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

A Phase 4 interventional study of olaparib and enzalutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 35 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.

Enrollment
13th of 25
43 · median 43
Started
2022
with 1 other
Phase 4
Only one
of the 25
Primary completion
2024-10
later than 3 of 10 live
Registered
21st of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is the only one in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 21st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing olaparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.

Read the detailed description

This is a Phase IV, randomized, open-label, 2-arm, multicenter study evaluating the efficacy and safety of olaparib in Chinese men with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have BRCA1/2 mutations. Approximately 42 subjects will be randomized in a 2:1 ratio to olaparib or to investigator's choice of NHA (enzalutamide or abiraterone acetate).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • metastatic castration-resistant prostate cancer (mCRPC)
  • BRCA1/2 mutations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of prostate cancer.
  2. Documented evidence of castration resistant prostate cancer (mCRPC).
  3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .
  4. Ongoing therapy with LHRH analog or bilateral orchiectomy.
  5. Radiological progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).
  6. Deleterious or suspected deleterious BRCA1/2 mutation in tumor tissue.
  7. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
  8. (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.

Exclusion criteria

Exclusion criteria:

  1. Any previous treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor, including olaparib.
  2. Subjects who had any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose > 5 years prior to randomization.
  3. History of another primary except for malignancy treated with curative intent with no known active disease for ≥5 years before the first dose of study intervention and of low potential risk for recurrence.
  4. Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 4 weeks prior to start of study intervention.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Olaparib

    Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions

    Drug: olaparib

  • Active comparator
    Enzalutamide OR abiraterone acetate

    Enzalutamide: Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily. Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily. Prednisone is 5mg twice daily. Prednisolone is permitted for use instead of prednisone if necessary.

    Drug: enzalutamide · Drug: abiraterone acetate · Drug: Prednisone

Interventions

  • 300 mg (2x 150 mg tablets) twice daily

    Also known as: Lynparza

  • 160 mg (4 x 40 mg capsules) once daily

    Also known as: XTANDI

  • 1,000 mg (4 x 250 mg tablets) once daily

    Also known as: ZYTIGA

  • 5mg(5mg x 1 tablet) twice daily

06

What researchers measure

Primary outcomes

  1. Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)

    rPFS is defined as the time from randomization until the date of objective disease progression (soft tissue or bone) or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression.

    Time frame: Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).

Secondary outcomes

  1. Confirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR)

    Confirmed ORR is the percentage of patients with a Complete response (CR) or Partial response (PR), in their soft tissue disease per (RECIST v1.1), in the absence of progression on bone scan per Prostate Cancer Working Group 3 (PCWG3), confirmed \>=4 weeks later. Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions. For each treatment group, confirmed ORR is the number of patients with a confirmed CR or PR divided by the number of patients in the treatment group.

    Time frame: Tumor assessments every 8 weeks (± 1 week) from randomisation until radiographic progression assessed by BICR (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).

  2. Overall Survival

    OS is the time from the date of randomization until death due to any cause.

    Time frame: From the time from the date of randomization until death due to any cause. Assessments continue up to 27 months after the first patient was randomized.

  3. Time to First Symptomatic Skeletal-related Event

    Time from first dose to the first symptomatic skeletal-related event

    Time frame: Time from randomization to the first SSRE-radiation for skeletal symptoms, confirmed pathological fracture, confirmed spinal cord compression, or orthopaedic surgery for bone metastases. Assessments continue up to 27 months post first patient enrolled.

  4. Time to Opiate Use for Cancer-related Pain

    Time from randomization to opiate use for cancer-related pain

    Time frame: Opioid use will be recorded at baseline and at every study visit, including the safety follow-up visit. Assessments continue up to 27 months post first patient enrolled.

  5. Prostate-specific Antigen Response

    Proportion of participants achieving a ≥50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response)

    Time frame: Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.

  6. Prostate-specific Antigen Response

    Best percentage change from baseline in PSA is defined as the biggest reduction in PSA level compared with baseline (or the smallest increase in the absence of a reduction) taking account of all PSA values collected for each patient.

    Time frame: Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.

  7. Time From Randomization to Second Progression or Death

    Time from randomization to second progression by investigator assessment of radiological or clinical progression or death (PFS2)

    Time frame: Tumor assessments will be performed every 8 weeks (±7 days) after randomization until radiologic progression or death, unless the participant withdraws consent. Assessments continue up to 27 months post first patient enrolled.

  8. Subsequent Anticancer Therapy

    Time frame: Recorded from post discontinuation of study treatment up to primary data cut off date. Assessments continue up to 27 months post first patient enrolled.

07

Results

Posted Dec 19, 2025

Participant flow

Participant flow — Overall Study
MilestoneOlaparib 300 mg bdInvestigators Choice of NHA
Started2914
Completed00
Not completed2914
Withdrew: Withdrawal by subject02
Withdrew: Death103
Withdrew: Ongoing199

Outcome measures

PrimaryRadiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)

rPFS is defined as the time from randomization until the date of objective disease progression (soft tissue or bone) or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression.

Time frame:
Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Median · Months
Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)
MonthsOlaparib 300 mg bdInvestigators Choice of NHA
Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)9.331 (5.65 to 11.20)8.838 (1.77 to NA)
Statistical analysis
  • Olaparib 300 mg bd vs Investigators Choice of NHA · Log Rank · p = 0.726 (The 2-sided nominal p-values were calculated using the log-rank test stratified by the same variables selected in the primary pooling strategy, using the Breslow method for handling ties.) · Hazard ratio (hr): 1.19 · 95% CI 0.46 to 3.45The Hazard ratio and CI were calculated using a Cox Proportional Hazards model adjusted for the variables. The Efron approach was used for handling ties. A hazard ratio \<1 favours Olaparib 300 mg bd.
SecondaryConfirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR)

Confirmed ORR is the percentage of patients with a Complete response (CR) or Partial response (PR), in their soft tissue disease per (RECIST v1.1), in the absence of progression on bone scan per Prostate Cancer Working Group 3 (PCWG3), confirmed \>=4 weeks later. Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \>=30% decrease in the sum of diameters of target lesions. For each treatment group, confirmed ORR is the number of patients with a confirmed CR or PR divided by the number of patients in the treatment group.

Time frame:
Tumor assessments every 8 weeks (± 1 week) from randomisation until radiographic progression assessed by BICR (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Reported as:
Count of participants · Participants
Confirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR)
ParticipantsOlaparib 300 mg bdInvestigators Choice of NHA
Confirmed Objective Response Rate (ORR), Based on Blinded Independent Review (BICR)51
Statistical analysis
  • Olaparib 300 mg bd vs Investigators Choice of NHA · Regression, Logistic · p = 0.498 (A Fisher's exact test using mid p-values was used.) · Odds ratio (or): 2.40 · 95% CI 0.20 to 59.66Objective response rate compared using logistic regression adjusting for previous taxane use as a covariate. An odds ratio \>1 favours Olaparib 300 mg bd. CI calculated using profile likelihood method.
SecondaryOverall Survival

OS is the time from the date of randomization until death due to any cause.

Time frame:
From the time from the date of randomization until death due to any cause. Assessments continue up to 27 months after the first patient was randomized.
Reported as:
Median · Months
Overall Survival
MonthsOlaparib 300 mg bdInvestigators Choice of NHA
Overall Survival17.314 (13.90 to NA)NA (10.32 to NA)
Statistical analysis
  • Olaparib 300 mg bd vs Investigators Choice of NHA · Log Rank · p = 0.440 (The 2-sided nominal p-values were calculated using the log-rank test stratified by the same covariates and using the Breslow method for handling ties.) · Hazard ratio (hr): 1.66 · 95% CI 0.50 to 7.48The hazard ratio and CI were calculated using a Cox Proportional Hazards model with the Efron approach being used for handling ties, adjusting for covariates. A hazard ratio \<1 favours Olaparib 300 mg bd.
SecondaryTime to First Symptomatic Skeletal-related Event

Time from first dose to the first symptomatic skeletal-related event

Time frame:
Time from randomization to the first SSRE-radiation for skeletal symptoms, confirmed pathological fracture, confirmed spinal cord compression, or orthopaedic surgery for bone metastases. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Median · Months
Time to First Symptomatic Skeletal-related Event
MonthsOlaparib 300 mg bdInvestigators Choice of NHA
Time to First Symptomatic Skeletal-related EventNA (NA to NA)NA (NA to NA)
SecondaryTime to Opiate Use for Cancer-related Pain

Time from randomization to opiate use for cancer-related pain

Time frame:
Opioid use will be recorded at baseline and at every study visit, including the safety follow-up visit. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Median · Months
Time to Opiate Use for Cancer-related Pain
MonthsOlaparib 300 mg bdInvestigators Choice of NHA
Time to Opiate Use for Cancer-related PainNA (11.20 to NA)17.281 (1.31 to NA)
Statistical analysis
  • Olaparib 300 mg bd vs Investigators Choice of NHA · Log Rank · p = 0.604 (The 2-sided nominal p-value was calculated using the log-rank test stratified by the same variables selected in the primary pooling strategy, using the Breslow method for handling ties.) · Hazard ratio (hr): 0.71 · 95% CI 0.20 to 2.88The Hazard ratio and CI were calculated using a Cox Proportional Hazards model adjusted for the variables selected in the primary pooling strategy: none. The Efron approach was used for handling ties. A hazard ratio \<1 favours Olaparib 300 mg bd.
SecondaryProstate-specific Antigen Response

Proportion of participants achieving a ≥50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response)

Time frame:
Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Number · Percentage of participants
Prostate-specific Antigen Response
Percentage of participantsOlaparib 300 mg bdInvestigators Choice of NHA
Single visit response48 (29 to 67)36 (13 to 65)
Confirmed response41 (24 to 61)29 (8 to 58)
SecondaryProstate-specific Antigen Response

Best percentage change from baseline in PSA is defined as the biggest reduction in PSA level compared with baseline (or the smallest increase in the absence of a reduction) taking account of all PSA values collected for each patient.

Time frame:
Blood samples for PSA assessment will be collected at baseline and every 4 weeks throughout the treatment phase, including at the study treatment discontinuation visit. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Mean · Percentage change from baseline
Prostate-specific Antigen Response
Percentage change from baselineOlaparib 300 mg bdInvestigators Choice of NHA
Percentage change from baseline at Week 1237.2 ± 252.62-15.0 ± 53.84
Best percentage change from baseline-40.6 ± 60.06-22.7 ± 74.62
SecondaryTime From Randomization to Second Progression or Death

Time from randomization to second progression by investigator assessment of radiological or clinical progression or death (PFS2)

Time frame:
Tumor assessments will be performed every 8 weeks (±7 days) after randomization until radiologic progression or death, unless the participant withdraws consent. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Median · Months
Time From Randomization to Second Progression or Death
MonthsOlaparib 300 mg bdInvestigators Choice of NHA
Time From Randomization to Second Progression or DeathNA (15.41 to NA)NA (5.91 to NA)
Statistical analysis
  • Olaparib 300 mg bd vs Investigators Choice of NHA · Log Rank · p = 0.889 (The 2-sided nominal p-values were calculated using the log-rank test stratified by the same covariates and using the Breslow method for handling ties.) · Hazard ratio (hr): 0.89 · 95% CI 0.19 to 6.24The hazard ratio and CI were calculated using a Cox Proportional Hazards model with the Efron approach being used for handling ties, adjusting for covariates. A hazard ratio \<1 favours Olaparib 300 mg bd.
SecondarySubsequent Anticancer Therapy
Time frame:
Recorded from post discontinuation of study treatment up to primary data cut off date. Assessments continue up to 27 months post first patient enrolled.
Reported as:
Count of participants · Participants
Subsequent Anticancer Therapy
ParticipantsOlaparib 300 mg bdInvestigators Choice of NHA
Any post-discontinuation anti-cancer therapy143
Immunotherapy00
Hormonal therapy122
Taxane chemotherapy40
Platinum chemotherapy00
PARP inhibitor03
Other10

Adverse events

Collected over From the time of signature of the ICF, throughout the treatment period and until the 30-day follow-up period is completed or 27 months post first patient enrolled, whichever occurs earlier. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300mg bd10/29 (34.5%)13/29 (44.8%)28/29 (96.6%)
Investigators Choice of NHA3/14 (21.4%)5/14 (35.7%)13/14 (92.9%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventOlaparib 300mg bdInvestigators Choice of NHA
AnaemiaBlood and lymphatic system disorders4/290/14
Decreased appetiteMetabolism and nutrition disorders3/291/14
OsteomyelitisInfections and infestations0/291/14
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/291/14
HaematuriaRenal and urinary disorders0/291/14
Urinary retentionRenal and urinary disorders0/291/14
Deep vein thrombosisVascular disorders0/291/14
Cardiac failureCardiac disorders0/291/14
VomitingGastrointestinal disorders1/290/14
FatigueGeneral disorders1/290/14
Most frequent other events
Showing 10 of 67
Most frequent other events
EventOlaparib 300mg bdInvestigators Choice of NHA
AnaemiaBlood and lymphatic system disorders22/295/14
VomitingGastrointestinal disorders7/294/14
ConstipationGastrointestinal disorders7/293/14
Weight decreasedInvestigations7/293/14
White blood cell count decreasedInvestigations7/293/14
HyponatraemiaMetabolism and nutrition disorders7/293/14
Urinary tract infectionInfections and infestations2/293/14
Neutrophil count decreasedInvestigations6/293/14
Platelet count decreasedInvestigations6/293/14
HypercholesterolaemiaMetabolism and nutrition disorders0/293/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib 300 mg bdInvestigators Choice of NHATotal
Median68.0 (56 to 82)67.5 (52 to 75)68.0 (52 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 300 mg bdInvestigators Choice of NHATotal
Female000
Male291443
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib 300 mg bdInvestigators Choice of NHATotal
Hispanic or Latino000
Not Hispanic or Latino291443
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib 300 mg bdInvestigators Choice of NHATotal
American Indian or Alaska Native000
Asian291443
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

35 sites
  • Research Site
    Beijing, 100050, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chongqing, 408099, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jiaxing, 314001, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Kunming, 650101, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200002, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Taiyuan, 030000, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wanzhou, 404000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuxi, 214002, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xi'an, 710077, China
  • Research Site
    Zhengzhou, 450052, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment(https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure). "Yes" indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2024, 26 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 13, 2022
StartActual
Jul 29, 2022
Primary completionActual
Oct 22, 2024
CompletionEst.
Dec 31, 2026
Results first posted
Dec 19, 2025
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05457257
Lead sponsor
AstraZeneca
Collaborators
Merck Sharp & Dohme LLC, Foundation Medicine, Myriad Genetics, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Jul 29, 2022
Primary completion
Oct 22, 2024
Completion
Dec 31, 2026 (estimated)
Results posted
Dec 19, 2025
Last update
Apr 21, 2026

Study contacts

Fangjian Zhou, M.D.
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion